Contact Information
AddressWuxi AppTec (Shanghai) Co., Ltd
288 Fute Zhong Road
Waigaoqiao Free Trade Zone
Shanghai 200131, China
Chichung CHAN_icon
Phone+86 (21) 5046 2461
Emailchan_chichung@wuxiapptec.com
Contact in UMOffice: E12-3032
Tel: (853)8822 4934
Email: ChichungChan@umac.mo
Education
Ph.D.University of Ottawa
B.Sc.The Chinese University of Hong Kong
Positions
2015 – presentAdjunct Professor, Faculty of Health Sciences, University of Macau
2014-presentVice President of Biology, Domestic Discovery Services Unit, WuXi  AppTec, Shanghai, China
Research Interests
Oncology:

  • Translational research, patient-derived, cell-derived xenograft models

Diabetes and Obesity:

  • Steroyl CoA desaturase1
  • Protein tyrosine phosphatase-1B, lipogeneic pathway, exploratory targets

Hypertension:

  • Nitric oxide- releasing anti-hypertensives

Inflammatory Diseases and Pain:

  • Cyclooxygenase-2, prostaglandin E synthase

Respiratory Diseases:

  • 5-lipoxygenase, 5-LO Activating Protein
  • Phosphodiesterase E4
  • Neurokinin

Allergy, Asthma, Respiratory Diseases, Arterial Thrombosis:

  • Leukotrienes, prostaglandins, thromboxanes
Representative Publications
  1. Gu Q, Zhang B, Sun H, Xu Q, Tan Y, Wang G, Luo Q, Xu W, Yang S, Li J, Fu J, Chen L, Yuan S, Liang G, Ji Q, Chen S, Chan C-C, Zhou W, Xu X, Wang H, Fang DD.  Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development.  Oncotarget, 6: 20160-20176, 2015.
  2. Fang DD, Zhang B, Gu Q, Lira M, Xu Q, Sun H, Qian M, Sheng W, Ozeck M, Wang Z, Zhang C, Chen X, Chen KX, Li J, Chen SH, Christensen J, Mao, M, Chan C-C.  HIP-ALK, a novel ALK fusion variant that responds to crizotinib.  J. Thoracic Oncol.  9:285-294, 2014.
  3. Oballa R, Belair L, Black WC, Kely Bleasby, Chan C-C, Desroches C, Du X, Gordon R, Guay J, Guiral S, Hafey MJ, Hamelin E, Huang Z, Kennedy B, Lachance N, Landry F, Li CS, Mancini J, Normandin D, Pocai A, Powell DA, Ramtohul YK, Skorey K, Sorensen D, Sturkenboom W, Styhler, Waddleton DM, Wang H, Wong S, Xu L, Zhang L.  Development of a liver-targeted stearoyl-CoA desaturaase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dysilipidemia.  J Med Chem.  54: 5082-5096, 2011.
  4. Guay D, Beaulieu C, Belley M, Crane S, DeLuca J, Gareau Y, Hamel M, Henault M, Hyjazie H, Kargman S, Chan C-C, Xu L, Gordon R, Li L, Mamane Y, Morin N, Mancini J, Therien M, Tranmer G, Truong V, Wang Z and Li CS.  Synthesis and SAR of pyrimidine-based, non-nucleotide P2Y14 receptor antogonists.  Bioorg Med Chem Lett.  21: 2832-2835, 2011.
  5. Mamane Y, Chan C‑C, Lavallee G, Morin N, Xu LJ, Huang J, Gordon R, Thomas W, Lamb J, Schadt EE, Kennedy BK  and Mancini JA.  The C3a anaphylatoxin receptor is a key mediator of insulin resistance and functions by modulating adipose tissue macrophage infiltration and activation.  Diabetes, 2006-0217, 2009.
  6. Han Y, Belley M, Bayly C, Colucci J, Dufresne C, Giroux A, Lau CK, Leblanc Y, McKay D, Therien M, Wilson MC, Skorey K, Chan C-C, Scapin G, Kennedy BP.  Discovery of [(3-brom0-7-cyano-2-naphthyl)(difluoro) -methyl]phosphonic acid, a potent and orally active small molecule PTP1B inhibitor.   Bioorg Med Chem Lett.  18: 3200-3205, 2008.
  7. MacDonald D, Brideau C, Chan C-C, Falgueyret JP, Frenette F, Guay J, Hutchinson JH, Perrier H, Prasit P, Riendeau D, Tagari P, Therien M, Young RN, Girard Y.  Substituted 2,2-bisaryl-bicycloheptanes as novel and potent inhibitors of 5-lipoxygenase activating protein.  Bioorg Med Chem Lett.  18: 2023-2027, 2008.
  8. Leung WL and Chan C-C.  Intragastric nitroglycerin at a vasodilatory dose attenuates acidified aspirin-induced gastric mucosal injury.  Dig Dis Sci  52: 2229-2235, 2007.
  9. Belley M, Chan C-C, Gareau Y, Gallant M, Juteau H, Houde K, Lachance N, Labelle M, Sawyer N, Tremblay N, Lamontagne S, Carriere M-C, Denis D, Greig GM, Slipetz D, Gordon R, Chauret N, Li C, Zamboni R, Metters KM.  Comparison between two classes of selective EP3 antagonists and their biological activities.  Bioorg Med Chem Lett.  16:5639-42, 2006.
  10. Lankas GR, Leiting B, Roy RS, Eiermann GJ, Beconi MG, Biftu T, Chan C-C, Edmondson S, Feeney WP, He H, Ippolito DE, Kim D, Lyons KA, Ok HO, Patel RA, Petrov AN, Pryor KA, Qian X, Reigle L, Woods A, Wu JK, Zaller D, Zhang X, Zhu L, Weber AE, Thornberry NA.  Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes. 54(10):2988-94, 2005.
  11. Claveau D, Sirinyan M, Guay J, Gordon R, Chan C-C, Bureau Y, Riendeau D and Mancini J. Microsomal prostaglandin E synthase-1 is a major terminal synthase that is selectively up-regulated during cyclooxygenase-2-dependent prostaglandin E2 production in the rat adjuvant-induced arthritis model.  J. Immunol.  170: 4738-4744, 2003.
  12. Chan C-C. In vivo assays for COX-2.  In: Inflammatory Protocol, Winyard PG and Willoughby D, (Eds.),  Humana Press, Totowa, NJ, pp. 321-328,  2003.
  13. Robichaud A, Stamatiou PB, Jin S-L, Lachance N, MacDonald D, Laliberte F, Liu S, Huang Z., Conti M and Chan C-C. Deletion of phosphodiesterase 4D in mice shortens a2-adrenoceptor-mediated anaesthesia, a behavioural correlate of emesis.  J. Clin. Invest.  110: 1045-1052, 2002.
  14. Prasit P, Riendeau D, and Chan C-C. Discovery of VioxxÔ.  In: Therapeutic Roles of Selective COX-2 Inhibitors,  Vane J. and Botting RM, (Eds.), William Harvey Press, London, pp. 60-75, 2001.
  15. Mancini JA, Blood K, Guay J, Gordon R, Claveau D, Chan C-C and Riendeau D.  Cloning, expression and upregulation of inducible rat PGE synthase during LPS-induced pyresis and adjuvant induced arthritis.  J. Biol. Chem., 276: 4469-4475, 2001.
  16. Robichaud A, Savoie C, Stamatiou P, Tattersall FD and Chan C.-C. PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway.  Neuropharmacol.,  40:262-269, 2001.
  17. Nantel F, Denis D, Gordon R, Northey A, Cirino M, Metters KM and Chan C-C.  Distribution and regulation of cyclooxygenase-2 in carrageenan-induced inflammation. Br. J. Pharmacol., 128: 853-859, 1999.
  18. Elchebly M, Payette P, Michaliszyn E, Cromlish W, Collins S, Loy AL, Normandin D, Himms-Hagan J, Chan C-C, Ramachandran C, Gresser M, Tremblay ML and Kennedy BP.  Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science, 283(5407):1544-1548, 1999.
  19. Chan C-C, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, Gordon R, Guay J, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O’Neill GP, Ouellet M, Patrick D, Percival MD, Perrier H, Prasit P, Rodger I, Tagari P, Therien M, Vickers P, Visco D, Wang Z, Webb J, Wong E, Xu L-J, Young RN, Zamboni R, Riendeau D. Rofecoxib (Vioxx, MK-0966, 4-(4’-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone): a potent and orally active cyclooxygenase-2 inhibitor – pharmacological and biochemical profiles.  J. Pharmacol. Exp. Ther., 290: 551-560, 1999.
  20. Rodger IW and Chan C-C. Inducible cyclooxygenase (Cox-2): A target for novel anti-inflammatory drugs.  In: Neuroinflammation: Mechanisms and Management Wood PL (ed.), Humana Press Inc., Totowa, NJ, pp. 355 – 371, 1997.
  21. Chan C-C, Ecclestone P, Nicholson D, Metters K, Pon DJ and Rodger IW. LTD4 induced increases in cytosolic calcium in THP-1 cells:  dependence on extracellular calcium and inhibition with selective LTD4 receptor antagonists.   J. Pharmacol. Expt. Ther., 269: 891 – 896, 1994.
  22. Chan C-C.  Leukotrienes and Allergic Conjunctivitis.  In: New Trends in Lipid Mediators Research, Vol. 5 : Lipid Mediators in Eye Inflammation  Bazan NH (Ed), Karger, Basel, pp. 41 – 55, 1990.
  23. Chan C‑C, Nathaniel DJ, Yusko PJ, Hall RA and Ford‑Hutchinson AW. Inhibition of prostanoid‑mediated platelet aggregation in vivo and in vitro by 3‑hydroxymethyl‑dibenzo (b,f) thiepin 5,5‑dioxide (L‑640,035).  J. Pharmacol. Expt. Ther. 229: 276 ‑ 282, 1984.
Patents
  1. Chan C‑C and Ford‑Hutchinson AW.  Patent on the discovery that enalapril potentiates the anti‑thrombotic effects of a dibenzo‑thiepin derivative on arterial thrombosis formation.  U.S. Patent No. 4558037.
  2. Robichaud A, Savoie C and Chan C-C.  Assay for emetic activity.  WO0051646.
  3. Mancini J, Claveau D, Chan C-C, Visco DM and Nicholson D.  Treatment of rheumatoid arthritis by inhibition of PDE4.  WO2004021987.
Professional Activities
Journal reviewer board: Inflammation & Allergy – Drug Targets
Current membership:

  • Canadian Society of Pharmacology & Therapeutics
  • American Society of Clinical Oncology
  • American Association for Cancer Research
  • American Society for Pharmacology & Experimental Therapeutics
  • American Thoracic Society